| Drug General Information |
| Drug ID |
D0Y6GJ
|
| Former ID |
DNC005198
|
| Drug Name |
ZM-241385
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Terminated |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H15N7O2
|
| InChI |
InChI=1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22)
|
| InChIKey |
PWTBZOIUWZOPFT-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
5872167, 10258376, 11113871, 14777778, 26752042, 33500023, 47583755, 48253989, 49689263, 50004913, 57395306, 74452709, 85209362, 85286143, 85788128, 87557789, 99445241, 103335269, 104425547, 123120880, 126573933, 126671704, 126732675, 128979380, 134342403, 135153620, 135651364, 135698324, 136367717, 142362493, 143493374, 144231441, 152239922, 152344277, 162022764, 162103474, 163125961, 165247591, 170483731, 179293999, 186009071, 204356592, 223658729, 224964692, 226553674, 241182070, 241375177, 242060109, 252216642
|
| Target and Pathway |
| Target(s) |
Adenosine A1 receptor |
Target Info |
Inhibitor |
[3]
|
|---|
| Adenosine A2b receptor |
Target Info |
Inhibitor |
[4]
|
| Adenosine A2a receptor |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Morphine addictionhsa04015:Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Alcoholismhsa04015:Rap1 signaling pathway
|
|
Parkinson's disease
|
|
Alcoholism
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
RANKL Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Pathway Interaction Database
|
C-MYB transcription factor networkhif2pathway:HIF-2-alpha transcription factor network
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2b and AdenosinePW000445:Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Reactome
|
Adenosine P1 receptors
|
|
G alpha (i) signalling eventsR-HSA-417973:Adenosine P1 receptors
|
|
G alpha (s) signalling events
|
|
Surfactant metabolismR-HSA-187024:NGF-independant TRKA activation
|
|
Surfactant metabolism
|
|
WikiPathways
|
Nucleotide GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP80:Nucleotide GPCRs
|
|
Monoamine Transport
|
|
NGF signalling via TRKA from the plasma membrane
|
|
GPCR downstream signaling
|
|
GPCRs, Other
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 405). |
|---|
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006356) |
|---|
| REF 3 | J Med Chem. 2009 Dec 10;52(23):7640-52.2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. |
|---|
| REF 4 | Bioorg Med Chem. 2010 Mar 15;18(6):2081-8. Epub 2010 Feb 15.Synthesis of theophylline derivatives and study of their activity as antagonists at adenosine receptors. |
|---|
